The company plans to expand its CLIA testing and complete a major study in theUS, as it moves forward to open a joint venture inChinathat will support further commercial expansion and clinical utility research.
The company plans to move away from a centralized lab model to develop kits that can be used by any laboratory to perform its assays, focusing first on developing RUO kits and then clinical assay for lung cancer and more.
Researchers and commercial vendors highlighted new data and clinical utility, but also discussed challenges in validating and establishing liquid biopsy diagnostics.
With the certification, Resolution can offer its test to researchers and clinicians to help guide personalized therapies and direct patients into clinical trials.
The company is developing liquid biopsy tests to detect disease recurrence and drug resistance, but does not yet have a specific plan for its first commercial assay.
Clinical applications for the approach are already at hand, and are poised to expand as companies solidify the clinical validity and utility data behind their platforms.
Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.
Cancer-ID is a newly created consortium tasked with validating blood-based biomarkers, such as CTC, cfDNA, and miRNA to bring liquid biopsies into the clinic.
